Logo image of IRIX

IRIDEX CORP (IRIX) Stock Fundamental Analysis

NASDAQ:IRIX - Nasdaq - US4626841013 - Common Stock - Currency: USD

1.44  -0.06 (-4.32%)

Fundamental Rating

1

Taking everything into account, IRIX scores 1 out of 10 in our fundamental rating. IRIX was compared to 189 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of IRIX have multiple concerns. IRIX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

IRIX had negative earnings in the past year.
In the past year IRIX has reported a negative cash flow from operations.
IRIX had negative earnings in each of the past 5 years.
IRIX had negative operating cash flow in 4 of the past 5 years.
IRIX Yearly Net Income VS EBIT VS OCF VS FCFIRIX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5M -5M -10M

1.2 Ratios

IRIX's Return On Assets of -36.60% is in line compared to the rest of the industry. IRIX outperforms 40.64% of its industry peers.
Looking at the Return On Equity, with a value of -420.74%, IRIX is doing worse than 86.63% of the companies in the same industry.
Industry RankSector Rank
ROA -36.6%
ROE -420.74%
ROIC N/A
ROA(3y)-18.8%
ROA(5y)-20.86%
ROE(3y)-55.59%
ROE(5y)-48.4%
ROIC(3y)N/A
ROIC(5y)N/A
IRIX Yearly ROA, ROE, ROICIRIX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20 -40 -60 -80 -100

1.3 Margins

Looking at the Gross Margin, with a value of 38.82%, IRIX is doing worse than 69.52% of the companies in the same industry.
IRIX's Gross Margin has been stable in the last couple of years.
IRIX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 38.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.6%
GM growth 5Y0.5%
IRIX Yearly Profit, Operating, Gross MarginsIRIX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40

More info and screens

1

2. Health

2.1 Basic Checks

IRIX does not have a ROIC to compare to the WACC, probably because it is not profitable.
IRIX has more shares outstanding than it did 1 year ago.
IRIX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for IRIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IRIX Yearly Shares OutstandingIRIX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M
IRIX Yearly Total Debt VS Total AssetsIRIX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -2.75, we must say that IRIX is in the distress zone and has some risk of bankruptcy.
IRIX has a Altman-Z score of -2.75. This is in the lower half of the industry: IRIX underperforms 64.17% of its industry peers.
A Debt/Equity ratio of 0.55 indicates that IRIX is somewhat dependend on debt financing.
IRIX has a worse Debt to Equity ratio (0.55) than 64.71% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF N/A
Altman-Z -2.75
ROIC/WACCN/A
WACC9.06%
IRIX Yearly LT Debt VS Equity VS FCFIRIX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M 30M

2.3 Liquidity

IRIX has a Current Ratio of 1.54. This is a normal value and indicates that IRIX is financially healthy and should not expect problems in meeting its short term obligations.
IRIX has a Current ratio of 1.54. This is in the lower half of the industry: IRIX underperforms 75.40% of its industry peers.
A Quick Ratio of 0.85 indicates that IRIX may have some problems paying its short term obligations.
IRIX has a worse Quick ratio (0.85) than 85.56% of its industry peers.
Industry RankSector Rank
Current Ratio 1.54
Quick Ratio 0.85
IRIX Yearly Current Assets VS Current LiabilitesIRIX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

More info and screens

2

3. Growth

3.1 Past

The earnings per share for IRIX have decreased strongly by -39.58% in the last year.
Looking at the last year, IRIX shows a very negative growth in Revenue. The Revenue has decreased by -11.33% in the last year.
The Revenue has been growing slightly by 4.02% on average over the past years.
EPS 1Y (TTM)-39.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.09%
Revenue 1Y (TTM)-11.33%
Revenue growth 3Y12.58%
Revenue growth 5Y4.02%
Sales Q2Q%-9.88%

3.2 Future

The Earnings Per Share is expected to grow by 23.82% on average over the next years. This is a very strong growth
The Revenue is expected to decrease by -1.86% on average over the next years.
EPS Next Y10.1%
EPS Next 2Y23.82%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-8.66%
Revenue Next 2Y-1.86%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
IRIX Yearly Revenue VS EstimatesIRIX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
IRIX Yearly EPS VS EstimatesIRIX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IRIX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IRIX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IRIX Price Earnings VS Forward Price EarningsIRIX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IRIX Per share dataIRIX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

IRIX's earnings are expected to grow with 23.82% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.82%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IRIX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IRIDEX CORP

NASDAQ:IRIX (2/24/2025, 8:00:02 PM)

1.44

-0.06 (-4.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)03-06 2025-03-06/amc
Inst Owners19.45%
Inst Owner Change-81.62%
Ins Owners3.68%
Ins Owner Change2.1%
Market Cap23.96M
Analysts43.33
Price Target2.04 (41.67%)
Short Float %2.22%
Short Ratio8.09
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-30.72%
Min EPS beat(2)-30.72%
Max EPS beat(2)-30.72%
EPS beat(4)0
Avg EPS beat(4)-96.49%
Min EPS beat(4)-252.94%
Max EPS beat(4)-30.72%
EPS beat(8)2
Avg EPS beat(8)-49.04%
EPS beat(12)5
Avg EPS beat(12)-31.74%
EPS beat(16)9
Avg EPS beat(16)-14.2%
Revenue beat(2)0
Avg Revenue beat(2)-6.22%
Min Revenue beat(2)-9.18%
Max Revenue beat(2)-3.26%
Revenue beat(4)0
Avg Revenue beat(4)-8.59%
Min Revenue beat(4)-18.03%
Max Revenue beat(4)-3.26%
Revenue beat(8)0
Avg Revenue beat(8)-6.95%
Revenue beat(12)2
Avg Revenue beat(12)-4.63%
Revenue beat(16)5
Avg Revenue beat(16)-1.01%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.49
P/FCF N/A
P/OCF N/A
P/B 9.14
P/tB 89.74
EV/EBITDA N/A
EPS(TTM)-0.67
EYN/A
EPS(NY)-0.28
Fwd EYN/A
FCF(TTM)-0.42
FCFYN/A
OCF(TTM)-0.42
OCFYN/A
SpS2.91
BVpS0.16
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -36.6%
ROE -420.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 38.82%
FCFM N/A
ROA(3y)-18.8%
ROA(5y)-20.86%
ROE(3y)-55.59%
ROE(5y)-48.4%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.6%
GM growth 5Y0.5%
F-Score2
Asset Turnover1.61
Health
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.62%
Cap/Sales 0.06%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.54
Quick Ratio 0.85
Altman-Z -2.75
F-Score2
WACC9.06%
ROIC/WACCN/A
Cap/Depr(3y)31.79%
Cap/Depr(5y)26.84%
Cap/Sales(3y)0.37%
Cap/Sales(5y)0.34%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-39.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.09%
EPS Next Y10.1%
EPS Next 2Y23.82%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-11.33%
Revenue growth 3Y12.58%
Revenue growth 5Y4.02%
Sales Q2Q%-9.88%
Revenue Next Year-8.66%
Revenue Next 2Y-1.86%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-30.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year21.05%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y29.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.34%
OCF growth 3YN/A
OCF growth 5YN/A